108060003951 Immunoglobulins Proteins 0.000 claims description 21.102000018358 Immunoglobulins Human genes 0.000 claims description 21.238000005215 recombination Methods 0.000 claims description 35.230000002401 inhibitory effect Effects 0.000 claims description 35.238000006467 substitution reaction Methods 0.000 claims description 83.108020004707 nucleic acids Proteins 0.000 claims description 93.150000007523 nucleic acids Chemical class 0.000 claims description 96.108010047041 Complementarity Determining Regions Proteins 0.000 claims description 96.125000003275 alpha amino acid group Chemical group 0.000 claims description 102.230000002950 deficient Effects 0.000 claims abstract description 15.231100000319 bleeding Toxicity 0.000 claims abstract description 16.230000000740 bleeding Effects 0.000 claims abstract description 16.206010018987 Haemorrhage Diseases 0.000 claims abstract description 16.230000002708 enhancing Effects 0.000 claims abstract description 17.230000004913 activation Effects 0.000 claims abstract description 33.201000003542 factor VIII deficiency Diseases 0.000 claims abstract description 35.102000038129 antigens Human genes 0.000 claims abstract description 267.108091007172 antigens Proteins 0.000 claims abstract description 267.239000000427 antigen Substances 0.000 claims abstract description 268.108090001123 antibodies Proteins 0.000 claims abstract description 379.102000004965 antibodies Human genes 0.000 claims abstract description 379.230000027455 binding Effects 0.000 claims abstract description 609.108010071919 Bispecific Antibodies Proteins 0.000 title description 33.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to GB1709970.6 priority Critical Priority to GBGB1709970.6A priority patent/GB201709970D0/en Application filed by Kymab Limited filed Critical Kymab Limited Publication of WO2018234575A1 publication Critical patent/WO2018234575A1/en Links Inventor Wei Wang E-Chiang Lee John Kenneth BLACKWOOD Roberto MAGLIOZZI Original Assignee Kymab Limited Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2018234575A1 - Bispecific antibodies for factor ix and factor x Tekko32 F4 Metal 4in1 ESC(65A) SPEC V1.WO2018234575A1 - Bispecific antibodies for factor ix and factor x M3 Anti-Vibration Silicone Grommet Insert *4Ĩpin to 8pin 1mm pitch 25mm cable *1 Downloads: The battery wire (from Lipo to 4in1 ESC) should be at least 12AWG and well soldered. Mounting holes: M4 30.5×30.5mm (M3 grommets included)Īir flow for the ESC is very important if you want to run this 4in1 in high current.1000uf 35v capacitor included (highly recommended for 6s setup).Supports DShot 150/300/600/1200 & MultiShot/OneShot/Proshot/PWM etc.Separate drive & control circuit, this broadens the current capability of the drive circuit while reducing the electrical interference to the control circuit.3 oz copper PCB design to allow bigger current and better heat dissipation.Massive on-board capacitance for noise filtering at 2068uf.Metal-cased MOSFET for excellent heat dissipation.New F4 MCU 150Mhz (compared to F3 & F0 PWM output up to 96K (default 48K).Rev v1.7 Updated: Amperage meter scale ratio: 180 Powerful & reliable metal-cased MOSFET 4in1 ESC with smooth control and quick response. The all new Tekko32 Metal is the first 4in1 ESC in the market to adapt the fast F4 MCU. F4 MCU / Metal-Cased MOSFET / PWM output up to 96K / 4~6S / BLHeli32
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |